| __timestamp | Corcept Therapeutics Incorporated | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 4326000 |
| Thursday, January 1, 2015 | 36949000 | 226206000 |
| Friday, January 1, 2016 | 45240000 | 94391000 |
| Sunday, January 1, 2017 | 62416000 | 53821000 |
| Monday, January 1, 2018 | 81289000 | 35463000 |
| Tuesday, January 1, 2019 | 100359000 | 46456000 |
| Wednesday, January 1, 2020 | 105326000 | 71318000 |
| Friday, January 1, 2021 | 122356000 | 135256000 |
| Saturday, January 1, 2022 | 152848000 | 102708000 |
| Sunday, January 1, 2023 | 184259000 | 129620000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Corcept Therapeutics Incorporated and ImmunityBio, Inc. have shown distinct approaches over the past decade. From 2014 to 2023, Corcept Therapeutics consistently increased its SG&A expenses, peaking at approximately 184 million in 2023, a fivefold increase from 2014. This steady rise reflects their strategic investment in growth and expansion.
Conversely, ImmunityBio, Inc. exhibited more volatility. Their SG&A expenses spiked dramatically in 2015, reaching over 226 million, before stabilizing around 130 million in recent years. This fluctuation suggests a more reactive approach to market conditions.
While both companies have seen significant changes, Corcept's consistent growth in SG&A expenses may indicate a more controlled and strategic management style, potentially positioning them better for long-term sustainability.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ImmunityBio, Inc.
Breaking Down SG&A Expenses: Bausch Health Companies Inc. vs ImmunityBio, Inc.